Comparing Efficacy and Safety of CinnaGen Beta Erythropoietin (CinnaPoietin®) Versus Eprex® on the Treatment of Anemia in ESRD Hemodialysis Patients

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 156 participants.

Also called NCT03408639

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 156 participants (enrolled count) (from the registry)
Sponsor
Cinnagen (from the registry)
Registry
  • NCT NCT03408639
Other papers using this trial's data
  • Comparing Therapeutic Efficacy and Safety of Epoetin Beta and Epoetin Alfa in the Treatment of Anemia in End-Stage Renal Disease Hemodialysis Patients American journal of nephrology, 2018 DOI, PubMed 30253403, PMC6381861 Not in the PMC Open Access subset.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
Iran (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03408639. Randomized; quadruple masking; primary purpose treatment. Start 2016-06-22 (actual); primary completion 2017-07-19 (actual). Results posted on 2019-11-06.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Comparing Efficacy and Safety of CinnaGen Beta Erythropoietin (CinnaPoietin®) Versus Eprex® on the Treatment of Anemia in ESRD Hemodialysis Patients
Condition
Anemia in End-Stage Renal Disease
Intervention (Drug)
CinnaPoietin®
Intervention (Drug)
Eprex®
Intervention (Drug)
Nephrovit
Intervention (Drug)
Vitamin B12 Injection
Lead sponsor
Cinnagen (class: industry)

Record details

Record id
cardio:ct-nct03408639
Content hash
74e0b96822d7d4c430555efe2e1d29e60124fc5d6db738c01be60a2fcc9c35ea